67,818
Participants
Start Date
January 1, 2015
Primary Completion Date
December 31, 2024
Study Completion Date
May 1, 2025
EGFR-TKI
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)-including gefitinib, erlotinib, afatinib, and osimertinib
PD-1/PD-L1 inhibitor
ICIs such as nivolumab, pembrolizumab, and atezolizumab-targeting the programmed cell death 1 (PD-1) or its ligand (PD-L1)
EGFR-TKI combined with PD-1/PD-L1
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)-including gefitinib, erlotinib, afatinib, and osimertinib combined with ICIs such as nivolumab, pembrolizumab, and atezolizumab-targeting the programmed cell death 1 (PD-1) or its ligand (PD-L1)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER